FDA approves breast cancer treatment, Nerlynx
by Press Release from Outbreak News Today on (#2WQ8Q)
The U.S. Food and Drug Administration today approved Nerlynx (neratinib) for the extended adjuvant treatment of early-stage, HER2-positive breast cancer. For patients with this type of cancer, Nerlynx is the first extended adjuvant therapy, a form of therapy that is taken after an initial treatment to further lower the risk of the cancer coming back. ["]
The post FDA approves breast cancer treatment, Nerlynx appeared first on Outbreak News Today.